AU2021391951A1 - Treatment of hemophilia with fitusiran - Google Patents

Treatment of hemophilia with fitusiran Download PDF

Info

Publication number
AU2021391951A1
AU2021391951A1 AU2021391951A AU2021391951A AU2021391951A1 AU 2021391951 A1 AU2021391951 A1 AU 2021391951A1 AU 2021391951 A AU2021391951 A AU 2021391951A AU 2021391951 A AU2021391951 A AU 2021391951A AU 2021391951 A1 AU2021391951 A1 AU 2021391951A1
Authority
AU
Australia
Prior art keywords
fitusiran
patient
level
patients
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021391951A
Other languages
English (en)
Other versions
AU2021391951A9 (en
Inventor
Shauna Andersson
Pratik R. BHAGUNDE
Yue CUI
Sajida IQBAL
Baisong Mei
Stacey POLOSKEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2021391951A1 publication Critical patent/AU2021391951A1/en
Publication of AU2021391951A9 publication Critical patent/AU2021391951A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8128—Antithrombin III
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2021391951A 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran Pending AU2021391951A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063121973P 2020-12-06 2020-12-06
US63/121,973 2020-12-06
US202163272629P 2021-10-27 2021-10-27
US63/272,629 2021-10-27
US202163275344P 2021-11-03 2021-11-03
US63/275,344 2021-11-03
PCT/US2021/062078 WO2022120292A1 (en) 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran

Publications (2)

Publication Number Publication Date
AU2021391951A1 true AU2021391951A1 (en) 2023-07-20
AU2021391951A9 AU2021391951A9 (en) 2024-05-02

Family

ID=80112089

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021391951A Pending AU2021391951A1 (en) 2020-12-06 2021-12-06 Treatment of hemophilia with fitusiran

Country Status (10)

Country Link
US (1) US20240027478A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255566A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023552554A (cg-RX-API-DMAC7.html)
KR (1) KR20230117403A (cg-RX-API-DMAC7.html)
AU (1) AU2021391951A1 (cg-RX-API-DMAC7.html)
CA (1) CA3204344A1 (cg-RX-API-DMAC7.html)
IL (1) IL303452A (cg-RX-API-DMAC7.html)
MX (1) MX2023006651A (cg-RX-API-DMAC7.html)
TW (1) TW202237151A (cg-RX-API-DMAC7.html)
WO (1) WO2022120292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3258425A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran in pediatric patients
EP4612687A1 (en) 2022-11-02 2025-09-10 Genzyme Corporation Systems and methods for modeling thrombin-antithrombin
TW202525306A (zh) * 2023-09-15 2025-07-01 美商健臻公司 用非妥西蘭(fitusiran)治療a型血友病
WO2025171279A1 (en) * 2024-02-09 2025-08-14 Genzyme Corporation Treatment of hemophilia with fitusiran

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) * 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物

Also Published As

Publication number Publication date
TW202237151A (zh) 2022-10-01
EP4255566A1 (en) 2023-10-11
JP2023552554A (ja) 2023-12-18
US20240027478A1 (en) 2024-01-25
IL303452A (en) 2023-08-01
KR20230117403A (ko) 2023-08-08
AU2021391951A9 (en) 2024-05-02
MX2023006651A (es) 2023-08-02
WO2022120292A1 (en) 2022-06-09
CA3204344A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
US20240027478A1 (en) Treatment of hemophilia with fitusiran
WO2022120291A1 (en) Treatment of hemophilia with fitusiran
US20220252593A1 (en) Methods of Treating Transthyretin (TTR) Mediated Amyloidosis
US20260014188A1 (en) Methods and compositions for treating hemophilia
JP2025519491A (ja) 小児患者における血友病a及びbの処置のためのフィツシラン
US20240000744A1 (en) Treatment of Hemophilia with Fitusiran
TW202525306A (zh) 用非妥西蘭(fitusiran)治療a型血友病
US20250064842A1 (en) Fitusiran for Use in Improving Patient-Reported Outcome in Hemophilia Patients
CN116635040A (zh) 用非妥西兰治疗血友病
EP3581196A1 (de) Inhibitoren des transferrinrezeptor-2 zur verwendung bei der behandlung von erkrankungen des knochens, des eisenstoffswechsels und der blutbildung
HK40088348A (en) Methods of treating transthyretin (ttr) mediated amyloidosis
HK40056298A (en) Modified factor vii polypeptides for subcutaneous administration
HK1240525B (en) Patisiran for use in treating transthyretin mediated amyloidosis
HK1240525A1 (en) Patisiran for use in treating transthyretin mediated amyloidosis

Legal Events

Date Code Title Description
SREP Specification republished